Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial

2017 ◽  
Vol 14 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Hong-Hwa Chen ◽  
Jen-Kou Lin ◽  
Joe-Bin Chen ◽  
Chieh-Han Chuang ◽  
Mei-Ching Liu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Metastatic Colorectal Cancer ◽  
Neoadjuvant Therapy ◽  
Phase Ii ◽  
Open Label ◽  
Noncomparative Trial ◽  
Unresectable Liver Metastases

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer

2014 ◽  
Vol 50 (18) ◽  
pp. 3136-3144 ◽  
Author(s):  
Tamas Hickish ◽  
Jim Cassidy ◽  
David Propper ◽  
Ian Chau ◽  
Stephen Falk ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Open Label ◽  
Open Label Phase

scholarly journals An Open‐Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX‐6 as First‐Line Therapy for Metastatic Colorectal Cancer

2014 ◽  
Vol 19 (4) ◽  
pp. 350-351 ◽  
Author(s):  
Rocio Garcia‐Carbonero ◽  
Fernando Rivera ◽  
Joan Maurel ◽  
Jean‐Pierre M. Ayoub ◽  
Malcolm J. Moore ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
First Line ◽  
Open Label ◽  
Safety And Efficacy ◽  
First Line Therapy ◽  
Line Therapy ◽  
Open Label Phase

A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3658-3658
Author(s):  
T. H. Cartwright ◽  
T. Lopez ◽  
S. J. Vukelja ◽  
C. Encarnacion ◽  
K. A. Boehm ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
First Line Treatment

Phase I/II study of irinotecan, UFT, and leucovorin with hepatic arterial infusion in colorectal cancer patients with unresectable liver metastases: Preliminary results

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14549-14549
Author(s):  
T. Yamaguchi ◽  
H. Matsumoto ◽  
K. Takahashi ◽  
M. Yasutome ◽  
T. Mori
Keyword(s):  
Colorectal Cancer ◽  
Phase I ◽  
Liver Metastases ◽  
Phase Ii ◽  
Phase I Study ◽  
Phase Ii Study ◽  
Hepatic Arterial Infusion ◽  
Arterial Infusion ◽  
Unresectable Liver Metastases ◽  
Colorectal Cancer Patients

14549 Background: To determine the maximum-tolerated dose (MTD) and to evaluate the efficacy and tolerability of combination chemotherapy of irinotecan (CPT-11), UFT and leucovorin (LV) with hepatic arterial infusion (HAI) in colorectal cancer patients with unresectable liver metastases. Methods: Patients who had unresectable liver metastases from colorectal cancer were treated concurrently with intravenous CPT-11 on day1 of each 14-day treatment cycle with dose escalation, with orally UFT and LV on day 1–7 of each cycle, and with HAI of 5-FU on day 8–14 of each cycle. The primary objective of this phase I study was to determine the MTD of biweekly intravenous CPT-11 and UFT/LV with HAI of 5-FU. In the phase II study, the primary endpoint was to determine the response rate. Results: In the phase I study, the recommended dose of CPT-11 for phase II study was 140 mg/m2 combined with UFT 300 mg/m2/day, LV 75 mg/body/day and 5-FU 2,000 mg/body/week. Sixteen patients were enrolled onto the phase II study. The six patients treated at the recommended dose during the phase I study also included in the phase II analysis (n = 22). Median number of liver metastases was 12 (range, 3 to 35). Median size of maximum diameter was 6.3 cm (range, 2.0 to 12.0 cm). The most common adverse event was neutropenia. The complete and partial response rate totaled 81.8%. Median survival time has not been reached yet. Eleven patients (50.0%) were ultimately able to undergo liver resection. Conclusions: The combination chemotherapy of CPT-11 and UFT/LV with HAI was safe, well tolerate and effective in current population of the patients with unresectable liver metastases from colorectal cancer. Updated toxicity and response data will be available in the spring of 2007. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document